Cure My Disease

Don't miss your cure!

 Log in / Sign up

A blood test to predict spinal cord recovery?

NCT ID NCT07772297

Diagnosis Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study explores whether certain molecules in the blood, called RNA biomarkers, are different in people with cervical spondylotic myelopathy (CSM) compared to healthy individuals. Researchers will see if these markers relate to the severity of the condition and how patients recover after surgery. The goal is to develop a tool that combines blood markers with imaging and clinical exams to better predict patient outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood-based RNA biomarker testing
What this could lead to
If successful, this could lead to a simple blood test to help diagnose cervical myelopathy and predict how well patients recover after surgery.
What could go wrong
This is an early exploratory study with a small number of participants, so the findings may not be definitive or widely applicable. The blood markers may not prove reliable enough for clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include patients with cervical spondylotic myelopathy (CSM) receiving care at the UCSF Spine Center. Participants will undergo standard-of-care treatment and follow-up at UCSF, with research blood samples collected before surgery and at designated postoperative timepoints. Clinical, imaging, medical history, and patient-reported outcome data will also be collected throughout the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Healthy Inclusion Criteria: * Age \>18 * No neck pain * No radiculopathy or myelopathy symptoms * No trauma in the past 6 months * Does not meet exclusion criteria. CSM Inclusion Criteria: * Age \>18 * Diagnosis of/encompassed by/related to cervical spondylotic myelopathy, cervical myelopathy, ossification of posterior longitudinal ligament. Healthy Exclusion Criteria: * Age \<18. * Malignancy * Trauma in the past 6 months * Infectious etiology * Prior cervical spine surgery. * Symptoms of cervical radiculopathy, myelopathy or neck pain. CSM Exclusion Criteria: * Age \<18. * Malignancy * Trauma in the past 6 months * Infectious etiology. * Prior cervical spine surgery. * MRI or CT imaging demonstrating an alternative cause for cervical myelopathy that is not degenerative stenosis (i.e. transverse myelitis, tumor compressing cord, pathologic fracture).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical spondylotic myelopathy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical spondylotic myelopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UCSF Medical Center

    San Francisco, California, 94143, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.